In light of the above results showing that ApoA5 selectively suppressed the LPL-inhibitory activity of ANGPTL3/8, we considered previous reports showing that LXR agonists cause hypertriglyceridemia and decrease the expression of ApoA5 (32, 33). This evidence concerns the gene ANGPTL3 and hypertriglyceridemia.